english.prescrire.org > Spotlight > Archives : 2018 > Prescrire's ratings of new products and indications over the past 10 years

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2018 : 1 | 30 | 60

Prescrire's ratings of new products and indications over the past 10 years

Each spring, Prescrire International publishes a recap of the drugs reviewed in our French edition during the previous year. It includes a table summing up the ratings Prescrire's editors gave to the new drugs and indications reviewed during each of the past ten years.

 
 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Bravo  BRAVO
0 0 0 0 0 0 1 1 0 0
A Real Advance  A REAL ADVANCE
0 0 1 0 1 0 2 3 1 1 (b)
Offers an advantage  OFFERS AN ADVANTAGE
6 3 3 3 3 6 5 5 5 9 (c)
Possibly helpful  POSSIBLY HELPFUL
25 14 22 13 14 12 15 15 9 18
Nothing new  NOTHING NEW
57 62 49 53 42 48 35 43 56 45
Not acceptable  NOT ACCEPTABLE
23 19 19 16 15 15 19 15 15 15 (d)
Judgement reserved  JUDGEMENT RESERVED
9 6 3 7 7 9 10 6 5 4 (e)
TOTAL 120 104 97 92 82 90 87 87 92 92
See: the
year in
review		 2008
(pdf)		 2009
(pdf)		 2010
(pdf)		 2011
(pdf)		 2012
(pdf)		 2013
(pdf)		  2014
(pdf)		 2015
(pdf)		 2016
(pdf)		 2017
(pdf)
For details on these categories, see: > Prescrire's drug ratings


a- About this table

This table includes new products (except generics) and new indications as well as our updated reviews (A second look).

b- The only drug rated "A REAL ADVANCE" in 2017 was:

  • Asfotase alfa in hypophosphatasia (Prescrire Int n° 187).

c- The drugs rated "OFFERS AN ADVANTAGE" in 2017 were:

  • emtricitabine + tenofovir disoproxil in the prevention of HIV transmission (Prescrire Int n° 187);
  • eribulin in inoperable refractory or relapsed liposarcoma (Prescrire Int n° 187);
  • methotrexate SC in prefilled pens (Rev Prescrire n° 404);
  • methotrexate injection in ectopic pregnancies (Prescrire Int n° 190);
  • oral nitisinone in type 1 tyrosinemia (Rev Prescrire n° 410);
  • nivolumab in metastatic renal cancers, in 2nd line after failure of a tyrosine kinase inhibitor (Prescrire Int n° 185);
  • pertuzumab in metastatic breast cancer (Prescrire Int n° 184);
  • raltegravir granules for oral suspension in infants infected with HIV (Prescrire Int n° 185);
  • sofosbuvir + velpatasvir in hepatitis C (Prescrire Int n° 192).

d- The drugs rated "NOT ACCEPTABLE" in 2017 were:

  • adalimumab in hidradenitis suppurative in adolescents (Prescrire Int n° 181);
  • ataluren in Duchenne muscular dystrophy (Prescrire Int n° 189);
  • bevacizumab 1st line in lung cancers (Prescrire Int n° 188);
  • brentuximab vedotin in Hodgkin lymphoma (Prescrire Int n° 191);
  • equine estrogens + bazedoxifene in menopausal symptoms (Prescrire Int n° 184);
  • everolimus in non functioning neuroendocrine tumours (Rev Prescrire n° 405);
  • fentanyl iontophoretic in pain (Rev Prescrire n° 409);
  • guanfacine for attention deficit with hyperactivity (Prescrire Int n° 186);
  • nivolumab in Hodgkin lymphoma after failure of an autologous stem cell transplant and brentuximab vedotin (Prescrire Int n° 191);
  • palbociclib in inoperable or metastatic breast cancers (Rev Prescrire n° 410);
  • pertuzumab before breast cancer surgery (Prescrire Int n° 184);
  • reslizumab in asthma (Rev Prescrire n° 410);
  • selexipag in pulmonary arterial hypertension (Prescrire Int n° 186);
  • tolvaptan in autosomal dominant polycystic kidney disease (Prescrire Int n° 187);
  • vandetanib in medullary thyroid cancer in children (Rev Prescrire n° 408).

e- The drugs rated "JUDGEMENT RESERVED" in 2017 were:

  • ivacaftor in cystic fibrosis (Prescrire Int n° 188);
  • ivacaftor + lumacaftor in cystic fibrosis (Prescrire Int n° 188);
  • pembrolizumab monotherapy in metastatic or inoperable lung cancers (Rev Prescrire n° 407);
  • teduglutide in short bowel syndrome in children (Rev Prescrire n° 404).

©Prescrire 1 April 2018

"Drugs in 2017: a brief review" Prescrire Int 2018; 27 (192): 110-111. (Pdf, free)
Download the full review.
Pdf, free

For more information:

New drugs and indications
in 2017: numerous innovations
offering no progress
(April 2018)
Free

See also:

The year in review:
New drugs and new
indications in 2016
(May 2017)
Free
 
Prescrire's drug ratings
(February 2018)
Free

The Prescrire Drug Awards
for 2017
(January 2018)
Free